Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.
Theodore G LiouFrederick R AdlerNatalia ArgelFadi AsfourPerry S BrownBarbara A ChatfieldCori L DainesDixie DurhamJessica A FrancisBarbara GloverTheresa HeynekampJohn R HoidalJudy L JensenRuth KeoghCarol M KopeckyNoah LechtzinYanping LiJerimiah LysingerOsmara MolinaCraig NakamuraKristyn A PackerKatie R PochAlexandra L QuittnerPeggy RadfordAbby J RedwayScott D SagelShawna SprandelJennifer L Taylor-CousarJane B VroomRyan YoshikawaJohn P ClancyJ Stuart ElbornKenneth N OlivierDavid R CoxPublished in: BMC medical research methodology (2019)
Randomly-selected, sputum-producing patients within the MWCFC represent sputum-producing patients in the CFFPR. They have similar characteristics, lung function and frequencies of pulmonary exacerbations, microbial infections and use of CF-specific treatments. These findings will plausibly make future interpretations of quantitative measurements of inflammatory biomarkers generalizable to sputum-producing patients in the CFFPR.